Immutep Ltd
Company Profile
Business description
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3’s ability to stimulate the body’s immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Contact
264 George Street
Level 32, Australia Square
SydneyNSW2000
AUST: +61 283157003
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
51
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
stocks
Undervalued ASX retailer benefiting from rebound in spending
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,869.40 | 21.00 | 0.24% |
| CAC 40 | 8,106.16 | 0.00 | 0.00% |
| DAX 40 | 24,076.87 | 153.04 | -0.63% |
| Dow JONES (US) | 48,114.26 | 302.30 | -0.62% |
| FTSE 100 | 9,684.79 | 66.52 | -0.68% |
| HKSE | 25,261.56 | 26.15 | 0.10% |
| NASDAQ | 23,111.46 | 54.05 | 0.23% |
| Nikkei 225 | 49,442.62 | 59.33 | 0.12% |
| NZX 50 Index | 13,385.13 | 39.82 | -0.30% |
| S&P 500 | 6,800.26 | 16.25 | -0.24% |
| S&P/ASX 200 | 8,581.00 | 17.40 | 0.20% |
| SSE Composite Index | 3,831.30 | 6.49 | 0.17% |